Next Article in Journal
A Silent Saboteur of Immunotherapy: Antibiotic Use and Its Impact on Immune Checkpoint Inhibitors Efficacy, a Systematic Review and Meta-Analysis of Recent Studies
Previous Article in Journal
Beyond Gastric Specificity: V-Set and Immunoglobulin Domain-Containing 1 (VSIG1) in Digestive Tract Tumors
Previous Article in Special Issue
Metabolic Crosstalk in Triple-Negative Breast Cancer Lung Metastasis: Differential Effects of Vitamin D and E in a Co-Culture System
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 18
Issue 5
10.3390/cancers18050868
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Effect of Healthy and Tumor-Associated Breast Adipose Tissue on Breast Cancer Cell Migration and Activation

by
Iris L. Holt-Kedde
1,*,
Hetty Timmer-Bosscha
2,
Frank A. E. Kruyt
2,
Wendy Kelder
3,
Bert van der Vegt
4,
Mieke C. Zwager
4,
Carolien P. Schröder
5 and
Marlous Arjaans
6
1
Department of Plastic Surgery, University of Groningen, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands
2
Department of Medical Oncology, University of Groningen, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands
3
Department of Surgery, Martini Hospital Groningen, 9728 NT Groningen, The Netherlands
4
Department of Pathology, University of Groningen, University Medical Center Groningen, 9714 GZ Groningen, The Netherlands
5
Department of Medical Oncology, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands
6
Department of Plastic Surgery, OLVG Medical Center, 1061 AE Amsterdam, The Netherlands
*
Author to whom correspondence should be addressed.
Cancers 2026, 18(5), 868; https://doi.org/10.3390/cancers18050868
Submission received: 10 February 2026 / Revised: 5 March 2026 / Accepted: 6 March 2026 / Published: 8 March 2026
(This article belongs to the Special Issue Tumor Microenvironment of Breast Cancer—2nd Edition)
Browse Figures
Versions Notes

Simple Summary

Breast fat tissue was once considered as only an energy source, but it actively releases signals that can influence nearby cells. Because obesity is linked to breast cancer risk and fat is increasingly used for breast reconstruction, we studied how breast fat tissue affects breast cancer cell behavior. We examined fat tissue from healthy women, women with inherited breast cancer risk genes, and breast cancer patients, and tested how it influenced breast cancer cell movement and activation in the laboratory. Importantly, we found that even healthy breast fat tissue can stimulate cancer cell movement, depending on the cancer type and body weight. This finding is especially relevant because the use of a woman’s own fat for breast reconstruction is increasing. Our results highlight the need for continued safety evaluation of fat-based reconstruction techniques to ensure long-term oncological safety.

Abstract

Background: Obesity is a recognized risk factor for developing breast cancer (BC), but factors involved remain unclear. We investigated if breast adipose tissue from healthy women, BRCA1/2 mutation carriers and BC patients, can stimulate BC cell line migration and activation. Methods: adipose tissue conditioned medium (ATCM), was prepared from breast adipose tissue from healthy subjects (naïve; group 1 (n = 20)), BRCA1/2 mutation carriers (group 2 (n = 22)) and BC patients (group 3 (n = 38)). ATCM effect on migration of BC cell lines MCF-7, SK-BR-3 and MDA-MB-231 was measured with xCELLigence (ACEA Biosciences, San Diego, CA, USA) cell migration assay. Activation of migration was determined by measuring filopodia activation. Migration and filopodia activation were related to body mass index (BMI) and BC subtypes. Luminex multiplex assay was performed to examine the secretory profile of adipose tissue. Results: ATCM from group 1 induced migration and filopodia activation in MCF-7 and MDA-MB-231, but not in SK-BR-3. ATCM from group 2 induced filopodia activation but no migration. ATCM from group 3 induced less migration in MCF-7 than ATCM from group 1. Higher BMI was associated with increased ATCM-induced activation in MCF-7 (group 1) and MDA-MB-231 (group 2). ATCM from group 1 and 2 showed a metabolic secretory profile, whereas group 3 showed higher pro-angiogenic and inflammatory cytokines. Conclusions: This study shows that breast adipose tissue from healthy women, BRCA1/2 mutation carriers and BC patients, can stimulate BC cell line migration and activation. This effect is related to BC subtype and BMI. These data improve insight in adipose tissue as factor in BC development.

1. Introduction

Breast cancer (BC) remains the leading cause of cancer-related mortality among women in developing countries and the second leading cause in developed countries [1]. Despite substantial advances in screening and therapy, a significant number of patients still develop locoregional recurrences and distant metastases, resulting in poor long-term outcomes. One of the established risk factors for BC is obesity. Women with obesity have a higher likelihood of developing BC, along with increased risks of locoregional recurrence, distant metastasis, and greater mortality from both BC and other causes [2,3,4,5,6].
During weight gain, adipose tissue undergoes systemic and local changes, including adipocyte hypertrophy, altered metabolism, and low-grade chronic inflammation [7,8,9,10]. Adipose tissue is no longer seen solely as an energy source, but as a metabolically active organ that secretes a wide range of cytokines, chemokines, adipokines, and hormones. Adipocytes in obese individuals may develop a pro-inflammatory and pro-tumorigenic secretory profile capable of influencing nearby epithelial or pre-malignant cells through paracrine signaling, thereby creating chances for tumor cells to flourish [11]. In the presence of BC cells, cancer associated adipocytes can contribute to tumor growth and local invasion [9,12,13,14,15,16,17,18]. Whether also naïve adipocytes (without previous exposure to BC) may exhibit BC subtype specific stimulation, particularly under obese conditions, remains insufficiently understood. In addition, some literature suggests that aromatase expression and cytokine production are different in BRCA1/2 mutation patients and may alter the adipose microenvironment [19,20].
Therefore, we investigated in an in vitro setting if breast adipose tissue from healthy women, BRCA1/2 mutation carriers and BC patients can stimulate BC cell line migration and activation, related to BC subtype and BMI.

2. Materials and Methods

2.1. Patient Inclusion and Tissue Collection

Patients were recruited from Academic Breast Center Groningen (location University Medical Center Groningen (UMCG) and Martini Hospital Groningen (MZH)). This study was approved by the Local ethics Review Board and all patients signed informed consent before inclusion (location UMCG number 202000066, approved on 18 May 2020 and location MZH number 2023-025. Approved on 22 February 2023)). Women undergoing elective breast surgery, including reduction mammoplasty, (preventive) mastectomy, or lumpectomy, were asked for permission to collect residual breast adipose tissue as per institutional care protocols. Adipose tissue was transported from the surgical suite in sterile phosphate-buffered saline (PBS) and divided into three study groups: 1. Adipose tissue from subjects undergoing breast reduction surgery (hereafter referred to as naïve adipose tissue), 2. Adipose tissue from BRCA1/2 gene mutation carriers (hereafter referred to as BRCA 1/2 adipose tissue) and 3. Adipose tissue from BC patients. Group 3 was further divided according to BC subtype (estrogen receptor-positive, ER+; human epidermal growth factor receptor 2-overexpressing, HER2+; or triple-negative breast cancer, TNBC, lacking ER, PR, and HER2 expression, as these breast cancer subtypes differ not only in receptor expression but also in their behavior, treatment strategies, and overall prognosis. Each study group was also subdivided according to BMI; normal weight (BMI ≥ 18.5 and < 25), overweight (BMI ≥ 25 and < 30) or obese (BMI ≥ 30). Clinical data regarding age, body mass index (BMI), BC subtype, BRCA1/2 gene mutation status, and history of neoadjuvant therapy were collected from the electronic patient files. Patients with metastatic or recurrent disease or a history of systemic therapy for cancer other than BC were excluded. An overview of the study groups in the different experimental settings is given in Figure 1.

2.2. Human Adipose Tissue Conditioned Medium

Preparation of Human ATCM was based on previous description by Wan et al., with some modifications [21]. Fresh adipose tissue samples (up to four per patient) were obtained per patient by the department of Pathology and processed within 1–2 h after collection. After washing and removal of non-adipose components, tissue fragments were cultured in DMEM-Low (Invitrogen, Carlsbad, CA, USA) supplemented with 1% fetal calf serum (FCS) and 1% penicillin-streptomycin at 37 °C and 5% CO2 for 48 h under sterile conditions.
After incubation, ATCM was collected, centrifuged to remove residual debris, and aliquoted into sterile 1 mL cryogenic vials. All aliquots were stored at −80 °C until further use in functional assays. A detailed description of the preparation protocol is provided in Supplementary Materials Method S1 and Figure S1.

2.3. BC Cell Lines

Three human BC cell lines representing different BC subtypes were used. MCF-7, (ER-positive), SK-BR-3 (HER-2 overexpressing) and MDA-MB-231 (triple negative) were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). Cell lines were cultured in DMEM-Low supplemented with 10% FCS and grown at 37 °C in a humidified atmosphere containing 5% CO2.
Upon reaching approximately 80% confluency, cells were starved for 24 h in DMEM containing 1% FCS before experimental procedures. All cell lines were routinely tested for Mycoplasma contamination, and their identity was confirmed by short tandem repeat profiling (BaseClear; Leiden, The Netherlands).

2.4. Migration Assay Using Real-Time Cell Analysis

Real-time monitoring of BC cell migration was performed using the xCELLigence RTCA DP system (Agilent Technologies, Santa Clara, CA, USA) with a CIM-plate 16 inserts. Cells (5 × 104 cells/well) were seeded in the upper chamber in DMEM-Low with 1% FCS. The lower chamber was filled with ATCM from the three study groups. Negative (1% FCS) and positive (20% FCS) controls were included in each assay. All samples were tested in triplicate.
Migration was monitored every 10 min for up to 60 h and expressed as corrected cell index (CI). Based on time-course analysis, 36 h was identified as the optimal time point for comparison. Detailed technical specifications and CI correction formulas are provided in Supplementary Materials Method S2 and Figure S2.

2.5. Filopodia Activation Assessment Using Scratch Assay

Cells were seeded on coverslips in 24-well plates and allowed to reach approximately 70% confluence. For MCF-7 cells, coverslips were coated with poly-L-lysine to maintain a confluent layer. After 24 h starvation, a scratch was created using a 1 mL pipette tip and cells were treated with 400 µL ATCM from groups 1–3 (group 3 matched to the BC subtype). Each experiment included negative (DMEM-Low with 1% FCS) and positive controls (DMEM-Low with 20% FCS).
After 24 h, cells were fixed with 4% methanol-free formaldehyde, permeabilized with 0.1% Triton, and stained for F-actin using fluorescent phalloidin. Nuclei were counterstained with DAPI. Slides were analyzed using an Axio Imager 2 microscope (Zeiss, Oberkochen, Germany).
Filopodia were visualized along the scratch edge and quantified using Fiji ImageJ ( version 2.14.0). Activation was assessed based on phalloidin staining intensity and visualized using the Fire lookup table (Figure 2). Filopodia activation was reported as the percentage of activated filopodia relative to the total number of filopodia.
Detailed staining procedures, imaging parameters, field selection strategy, and manual identification criteria are provided in Supplementary Materials Method S3.

2.6. Identifying Cytokines Using Luminex Assay

All 80 ATCM samples were analyzed using Luminex® multiplex immunoassays; Human Obesity (Catalog #FCSTM08 R&D Systems, Minneapolis, MN, USA) and XL Cytokine Premixed Panels (Catalog #FCSTM18B R&D Systems, Minneapolis, MN, USA), R&D Systems. Standards and samples were prepared according to kit instructions, with appropriate dilutions (1:2) made directly in 96-well plates. Microparticle cocktails were added and incubated at room temperature, followed by overnight incubation at 4 °C. The next day, plates were washed and sequentially incubated with biotinylated detection antibodies and Streptavidin-PE. Fluorescence was measured using a Luminex® 200 analyzer (Luminex Corporation, Austin, TX, USA), and analyte concentrations were determined from standard curves.

3. Results

3.1. Patients’ Characteristics and Human Breast Adipose Tissue Samples

Breast adipose tissue was collected from 80 patients in total, with 20, 22 and 38 samples for group (1) naïve, (2) BRCA1/2 and (3) BC, respectively. Detailed clinicopathological information is summarized in Table 1. Mean BMI was highest in ER+ BC patients (32.4 ± 3.3) and lowest among healthy individuals (26.7 ± 4.3). Patients with HER2+ BC were oldest (age 58 ± 15 years), whereas subjects with BRCA gene mutation were the youngest (33 ± 14 years). Neo-adjuvant treatment was administrated to 30.7% of TNBC and 14.3% of HER2+ patients (Table 1).

3.1.1. Group 1—Naïve Adipose Tissue (Naïve ATCM)

Naïve ATCM affected both migration and filopodia activation in a cell line-dependent manner. For migration, naïve ATCM stimulated motility in MCF-7 and MDA-MB-231 cells, whereas it inhibited migration in SK-BR-3 cells (H (2) = 13.5, p = 0.001) (Figure 3A). BMI modified these effects only in SK-BR-3 cells, where obese naïve ATCM further enhanced the inhibitory response compared to overweight naïve ATCM (H (2) = 7.109, p = 0.029) (Figure S3A). Naïve ATCM also induced filopodia activation in all three cell lines (H (2) = 34.4, p < 0.001). Activation was significantly lower in MCF-7 cells compared with MDA-MB-231 and SK-BR-3 (both p < 0.001) (Figure 3B). BMI influenced activation only in MCF-7 cells, where ATCM from overweight donors enhanced filopodia activation relative to normal weight donors (p = 0.030 and p = 0.048) (Figure S3B). Thus, naïve adipose tissue in group 1 induced migration of BC cells and this was subtype-dependent. In addition, filopodia activation was seen in all BC cell lines and this can be influenced by BMI.

3.1.2. Group 2—BRCA1/2 Gene Mutation Carrier-Derived Adipose Tissue (BRCA ATCM)

BRCA1/2 ATCM induced limited migration but significant filopodia activation. Migration was slightly increased in MCF-7 cells, with no effect on MDA-MB-231 or SK-BR-3 cells, and without BMI dependency (Figure S3C). In contrast, filopodia activation increased across all cell lines, with significantly higher activation in MDA-MB-231 and SK-BR-3 compared to MCF-7 (corrected p < 0.001 and p = 0.001) (Figure 4). BMI effects occurred only in MDA-MB-231 cells, where activation increased progressively with BMI status (NW vs. OB p = 0.020; OW vs. OB p = 0.004) (Figure S3D). Therefore, while BRCA adipose tissue in group 2 does not generally promote migration, it does enhance filopodia activation in BC cells.

3.1.3. Group 3—Breast Cancer Patient-Derived Adipose Tissue (BC ATCM)

ATCM derived from patients with ER+ BC, significantly decreased migration of MCF-7 compared to naïve ATCM (p = 0.036), and this effect was independent of BMI (Figure 5A and Figure S3E). In contrast, MCF-7 filopodia activation was strongly increased by ER BC ATCM compared to naïve ATCM and BRCA ATCM (both corrected p < 0.001) (Figure 5B). MCF-7 filopodia activation was significantly higher in overweight (p = 0.018) and obese (p = 0.031) ER+ BC ATCM (Figure S3F). Therefore, although ATCM derived from patients with ER+ BC suppresses migration in MCF-7 cells, it strongly enhances filopodia activation, particularly when BMI increases.
ATCM derived from patients with TNBC, increased both migration and filopodia activation of MDA-MB-231 cells. Migration was significantly increased compared to BRCA ATCM (p = 0.026), independent of BMI (Figure 5C and Figure S3G). Similarly, filopodia activation was markedly higher compared to naïve ATCM and BRCA ATCM (corrected p = 0.001 and p < 0.001), and this effect was independent of BMI (Figure 5D and Figure S3H). Therefore, TNBC BC ATCM simultaneously stimulates migration and filopodia activation in MDA-MB-231 cells, producing the strongest pro-invasive response among all groups and subtypes.
ATCM derived from patients with HER2+ BC, did not increase migration of SK-BR-3 cells, and potential BMI effects could not be assessed due to limited samples. Nevertheless, filopodia activation was significantly increased compared to BRCA ATCM (corrected p = 0.007), indicating cytoskeletal activation despite the absence of a migratory response (Figure 5E). Therefore, HER2+ BC ATCM derived from patients with enhances filopodia activation but does not induce migration in SK-BR-3 cells.
In summary, BC derived ATCM in group 3 induced stronger effects on migration and activation than ATCM from healthy subjects or BRCA mutation carriers, in a subtype-specific fashion.

3.2. Luminex Assay

ATCM of group 1 and 2 displayed a secretory profile with higher levels of adipokines and metabolic regulators (adiponectin, leptin), as well as Serpin E1 and TNF-α (all corrected p < 0.05) compared to group 3. ATCM from group 3 showed significantly elevated levels of cytokines involved in angiogenesis and tissue remodeling (VEGF, PDGF-AA, TGF-α, FGFb), pro-inflammatory signaling (IL-1β, IL-6, IL-8, IL-17, GRO-β, Lymphotoxin-α), immune cell activation and differentiation (CD40, GM-CSF, FLT3L, IFN-α, IL-2, IL-7, IL-12p70, IL-15), and cytotoxic/hematopoietic pathways (Granzyme B, IL-3, IL-5) (all corrected p < 0.05) were ATCM of ER+ showed the higher levels. The most pronounced increases were observed for VEGF and PDGF-AA (both corrected p < 0.001).
ATCM from ER+ patients showed broad upregulation across angiogenic, pro-inflammatory, and immune-activating cytokines (including IL-6, IL-8, TNF-α, PDGF-AA, VEGF, and PD-L1) compared with ATCM from BRCA 1/2 patients (all corrected p < 0.05). In contrast, ATCM from TNBC patients exhibited reduced secretion of inflammatory and angiogenic mediators (G-CSF, IFN-γ, IL-1β, IL-4, IL-6, PDGF-AB/BB, TNF-α) compared with ATCM from ER+ patients, while ATCM from naïve patients displayed higher levels of Serpin E1 and TNF-α relative to ATCM of TNBC patients (all corrected p < 0.05). HER2+ ATCM was marked by reduced secretion of the adipokines adiponectin and leptin compared with naïve ATCM (corrected p < 0.05) (Table 2).
Overall, obesity was associated with increased secretion of anti-inflammatory mediators. IL-1RA was higher in overweight compared with normal weight samples and further upregulated in obese compared with both normal weight and overweight samples (corrected p < 0.05). CRP levels followed a similar pattern, with higher secretion in obese versus normal weight and overweight samples (corrected p < 0.05) (Table 3).

4. Discussion

In this study we investigated the effect of adipose tissue from different settings on migration and activation of different BC cell subtypes. We showed that even adipose tissue from naïve subjects can induce migration and activation of BC cells in a subtype-dependent matter. In addition, adipose tissue from BRCA 1/2 mutation carriers and BC patients altered or enhanced these results. Cytokine profiling showed elevated levels of angiogenic and inflammatory cytokines in adipose tissue-conditioned media from BC patients. In contrast, non-cancer tissue had higher adipokines like adiponectin and leptin.
In contrast to previous research with co-cultures or adipose tissue stem cells (ASCs) -based conditioned media, in this study the supernatant of patient-derived adipose tissue was used, without extra activation steps [22]. Including patient-derived adipose tissue not only from BC patients but also healthy and BRCA carriers, enabled direct assessment of the effect of adipose tissue from different settings in different BC subtypes. Our findings strengthen the hypothesis that adipose tissue is not an innocent bystander but should be seen as an active player in the BC microenvironment.
The finding that naïve adipose tissue can affect migration of BC cells contributes to the debate on the oncologic safety of lipofilling and autologous fat grafting (AFT). Clinical studies report mixed safety outcomes: Berti et al. show elevated recurrence risk, while Claudio et al. and Navarro et al. found no increased risk when lipofilling occurs >36 months post-surgery or in patients without lymph node involvement [23,24,25]. Reviews generally support this safety but highlight selection bias and methodological limitations [26,27,28]. Due to standard treatments, exclusion of neoadjuvant-treated patients was not feasible. This could indicate treatment-related confounding [29,30,31]. To date, no in vitro studies have examined the effect of adipose tissue from survivors after completion of therapy on BC cells or compared secretion profiles before and after treatment. It is possible that adipose tissue normalizes over time, suggested as the ‘safe interval’ by Silva-Vergara C et al. [25]. However, our pre-clinical findings support continued caution. Identifying markers that distinguish regenerative from pro-tumorigenic signaling will be essential for the safe and personalized use of adipose tissue in breast reconstruction [32].
Filopodia activation was more pronounced in BC ATCM compared to naïve and BRCA ATCM. This observation aligns with prior descriptions that cancer-associated adipocytes and adipocyte-conditioned media promote cytoskeletal remodeling and protrusive activity in BC cells, as shown in several co-culture and ATCM studies [33]. In MCF-7 cells, ER+ ATCM reduced migration but increased filopodia activation, suggesting that activation of migratory machinery does not necessarily translate into movement. This was also previously described by Padilla-Rodriguez et al. [34]. This paradox also reflects the less invasive phenotype of ER+ tumors, consistent with clinical observations and prior studies [33,35,36]. TNBC cells responded strongly to TNBC-matched ATCM, showing increased migration and activation, in line with their aggressive nature and sensitivity to pro-inflammatory adipocyte signals [35,36,37]. BRCA-mutated ATCM did not show these effects, thus genetic background could possibly modulate adipocyte–tumor interactions. In contrast to other subtypes, HER2+ BC cells exhibited little to no migratory response to adipose tissue, and HER2+ ATCM was characterized by reduced adipokine secretion. Together, these findings suggest that HER2+ BC cells are less sensitive to adipose tissue-derived signals, consistent with HER2 signaling being the dominant oncogenic driver in this subtype.
Most of the previous work about interaction of adipose tissue and BC cells are BMI orientated. In this study we did not find strong BMI dependency in migration behavior. We did see that higher BMI was associated with increased filopodia activation in ER+ cells and increased secretion of cytokines (IL-1RA, CRP) which are markers of inflammation, in line with literature that show a chronic pro-tumorigenic microenvironment in obesity [33,37,38,39,40]. CRP has also shown to be associated with bad prognosis in BC [41]. These findings align with previous studies showing that adipocytes can promote BC progression via cytokines such as IL-6, leptin, and VEGF, with obesity amplifying these effects [33,40,42,43]. Although this points to BMI as the culprit, this could be more dependent on the metabolic state of the adipose tissue. Growing literature shows that adipose tissue can be ‘unhealthy’ in normal weight patients and ‘healthy’ in obese patients, suggesting that BMI might not always directly align with the metabolic activity of adipose tissue [44,45]. In the context of our results, this illustrates the need to identify better markers of metabolic activity of BC patients’ adipose tissue in the future.
This study has limitations. Patient samples of adipose tissue contain more than only adipocytes. There could be other cells or aliquots within the adipose tissue that could have influenced the results. Another limitation includes the small sample sizes, particularly in the HER2+ subgroup, reducing statistical power. Additionally, we could not fully exclude patients receiving neoadjuvant therapy, which may alter adipose characteristics [30,31]. On the other hand, neoadjuvant treatment is the mainstay treatment for HER2 positive BC and TNBC, and therefore these samples do reflect current clinical practice. Future studies should refine this model by culturing adipose-derived stem cells directly from adipose tissue and analyzing their secretion pattern, or by employing co-culture systems to better mimic the cellular interactions within the tissue environment [33,36,46].

5. Conclusions

This study shows that breast adipose tissue from healthy women, BRCA 1/2 mutation carriers and BC patients, can stimulate BC cell line migration and activation. This effect is related to BC subtype and BMI. These data improve insight in adipose tissue as factor in BC development.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/cancers18050868/s1, Method S1: ATCM Preparation Protocol; Method S2: Detailed Migration Assay Protocol and CI Correction; Method S3: Detailed Scratch Assay and Filopodia Quantification; Figure S1: An overview of the preparation of the ATCM (adipose tissue controlled medium).; Figure S2: Migration data for timepoints 24 hours in the top row and 48 hours in the bottom row. A; for naïve ATCM (group1), B; BRCA ACTM (group2) and C–E (group 3); C; MCF-7, D; MDA-MB-231 and E; SK-BR-3.; Figure S3: Migration and filopodia activation subdivided by BMI for group 1(A & B), group 2 (C & D) and group 3 (E–H). BMI groups are NW = normal weight (BMI < 25), OW = overweight (25 ≤ BMI < 30). OB=obese (BMI ≥ 30) which are shown from light to darker pink. Dotted black line represents zero migration, green line positive control (20% FCS) and red line represents negative control (5% FCS.) for the filopodia activation. (* p < 0.005, ** p = 0.001, *** p < 0.001) [21,47,48].

Author Contributions

Conceptualization, I.L.H.-K., M.A., H.T.-B. and C.P.S.; methodology, I.L.H.-K., M.A., H.T.-B. and C.P.S.; software, H.T.-B. and I.L.H.-K.; validation I.L.H.-K., M.A. and H.T.-B.; formal analysis, I.L.H.-K., M.A., H.T.-B., F.A.E.K. and C.P.S.; investigation, I.L.H.-K. and M.A.; resources, I.L.H.-K., W.K., B.v.d.V., M.A., H.T.-B., F.A.E.K. and C.P.S.; data curation, I.L.H.-K.; writing—original draft preparation, I.L.H.-K., M.A. and C.P.S.; writing—review and editing, I.L.H.-K., H.T.-B., M.A. and C.P.S.; visualization, I.L.H.-K.; supervision, M.A., H.T.-B. and C.P.S.; project administration, M.A., H.T.-B., I.L.H.-K. and W.K.; funding acquisition, M.A., C.P.S. and M.C.Z. All authors have read and agreed to the published version of the manuscript.

Funding

This research was supported by the Dutch Cancer Society grant RUG2010-4739 to C.P. Schröder, the Mandema stipend granted in 2016 to M. Arjaans by the University Medical Center Groningen and a grant from the Stichting De Cock-Hadders to M.C. Zwager.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki and approved by the Local Ethics Review Board location UMCG number 202000066, (approved on 18 May 2020) and location MZH number 2023-025 (Approved on 22 February 2023).

Informed Consent Statement

Written informed consent has been obtained from the patient(s) to publish this paper.

Data Availability Statement

The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.

Conflicts of Interest

B.v.d.V. reports honoraria received by UMCG for expertise or scientific advisory board/consultancy (on request): Visiopharm, Philips, MSD/Merck, Daiichi-Sankyo/AstraZenica; Speaker’s fee from Visiopharm, Diaceutics, MSD/Merck. All unrelated to the current publication. C.P.S. received unrestricted research grants from Pfizer, Seagen, Siemens, Gilead, not related to the content of this manuscript. The other authors report no competing interests.

Abbreviations

The following abbreviations are used in this manuscript:
BCBreast cancer
ATCMadipose tissue conditioned medium
BMIBody Mass Index
PBSphosphate-buffered saline
DMEMDulbecco’s Modified Eagle Medium
RTCAReal-Time Cell Analysis
NWNormal weight (BMI < 25)
OWOverweight (25 ≤ BMI < 30)
OBObese (BMI ≥ 30)

References

  1. Siegel, R.L.; Kratzer, T.B.; Giaquinto, A.N.; Sung, H.; Jemal, A. Cancer statistics, 2025. CA Cancer J. Clin. 2025, 75, 10–45. [Google Scholar] [CrossRef]
  2. Lohmann, A.E.; Soldera, S.V.; Pimentel, I.; Ribnikar, D.; Ennis, M.; Amir, E.; Goodwin, P.J. Association of Obesity with Breast Cancer Outcome in Relation to Cancer Subtypes: A Meta-Analysis. J. Natl. Cancer Inst. 2021, 113, 1465–1475. [Google Scholar] [CrossRef]
  3. Pang, Y.; Wei, Y.; Kartsonaki, C. Associations of adiposity and weight change with recurrence and survival in breast cancer patients: A systematic review and meta-analysis. Breast Cancer 2022, 29, 575–588. [Google Scholar] [CrossRef]
  4. Chan, D.S.M.; Vieira, A.R.; Aune, D.; Bandera, E.V.; Greenwood, D.C.; McTiernan, A.; Navarro Rosenblatt, D.; Thune, I.; Vieira, R.; Norat, T. Body mass index and survival in women with breast cancer—Systematic literature review and meta-analysis of 82 follow-up studies. Ann. Oncol. 2014, 25, 1901–1914. [Google Scholar] [CrossRef]
  5. Calle, E.E.; Kaaks, R. Overweight, obesity and cancer: Epidemiological evidence and proposed mechanisms. Nat. Rev. Cancer 2004, 4, 579–591. [Google Scholar] [CrossRef] [PubMed]
  6. Calle, E.E.; Rodriguez, C.; Walker-Thurmond, K.; Thun, M.J. Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults. N. Engl. J. Med. 2003, 348, 1625–1638. [Google Scholar] [CrossRef]
  7. Unamuno, X.; Gómez-Ambrosi, J.; Rodríguez, A.; Becerril, S.; Frühbeck, G.; Catalán, V. Adipokine dysregulation and adipose tissue inflammation in human obesity. Eur. J. Clin. Investig. 2018, 48, e12997. [Google Scholar] [CrossRef]
  8. Turner, L.; Wanasinghe, A.I.; Brunori, P.; Santosa, S. Is Adipose Tissue Inflammation the Culprit of Obesity-Associated Comorbidities? Obes. Rev. 2025, 26, e13956. [Google Scholar] [CrossRef]
  9. Razmkhah, M.; Jaberipour, M.; Hosseini, A.; Safaei, A.; Khalatbari, B.; Ghaderi, A. Expression profile of IL-8 and growth factors in breast cancer cells and adipose-derived stem cells (ASCs) isolated from breast carcinoma. Cell. Immunol. 2010, 265, 80–85. [Google Scholar] [CrossRef] [PubMed]
  10. Zwager, M.C.; Holt-Kedde, I.; Timmer-Bosscha, H.; de Bock, G.H.; Werker, P.M.N.; Schröder, C.P.; van der Vegt, B.; Arjaans, M. Presence of crown-like structures in breast adipose tissue; differences between healthy controls, BRCA1/2 gene mutation carriers and breast cancer patients. Breast Cancer Res. Treat. 2024, 204, 27–37. [Google Scholar] [CrossRef] [PubMed]
  11. Iyengar, N.M.; Gucalp, A.; Dannenberg, A.J.; Hudis, C.A. Obesity and cancer mechanisms: Tumor microenvironment and inflammation. J. Clin. Oncol. 2016, 34, 4270–4276. [Google Scholar] [CrossRef] [PubMed]
  12. Shah, D.D.; Chorawala, M.R.; Raghani, N.R.; Patel, R.; Fareed, M.; Kashid, V.A.; Prajapati, B.G. Tumor microenvironment: Recent advances in understanding and its role in modulating cancer therapies. Med. Oncol. 2025, 42, 117. [Google Scholar] [CrossRef]
  13. Asadi, M.; Zafari, V.; Sadeghi-Mohammadi, S.; Shanehbandi, D.; Mert, U.; Soleimani, Z.; Caner, A.; Zarredar, H. The role of tumor microenvironment and self-organization in cancer progression: Key insights for therapeutic development. BioImpacts 2025, 15, 30713. [Google Scholar] [CrossRef]
  14. Dumas, J.F.; Brisson, L. Interaction between adipose tissue and cancer cells: Role for cancer progression. Cancer Metastasis Rev. 2021, 40, 31–46. [Google Scholar] [CrossRef]
  15. Naser, R.; Fakhoury, I.; El-Fouani, A.; Abi-Habib, R.; El-Sibai, M. Role of the tumor microenvironment in cancer hallmarks and targeted therapy (Review). Int. J. Oncol. 2023, 62, 23. [Google Scholar] [CrossRef]
  16. Bonet, C.; Bou, M.C.; Tsilidis, K.K.; Gunter, M.J.; Kaaks, R. The association between body fatness and mortality among breast cancer survivors: Results from a prospective cohort study. Eur. J. Epidemiol. 2023, 38, 545–557. [Google Scholar] [CrossRef]
  17. Nalabolu, M.R.; Palasamudram, K.; Jamil, K. Adiponectin and leptin molecular actions and clinical significance in breast cancer. Int. J. Hematol. Stem Cell Res. 2014, 8, 31–40. [Google Scholar]
  18. Wronska, A.; Kmiec, Z. Structural and biochemical characteristics of various white adipose tissue depots. Acta Physiol. 2012, 205, 194–208. [Google Scholar] [CrossRef]
  19. Kotsopoulos, J.; Olopade, O.I.; Ghadirian, P.; Lubinski, J.; Lynch, H.T.; Isaacs, C.; Weber, B.; Kim-Sing, C.; Ainsworth, P.; Foulkes, W.D.; et al. Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 2005, 7, 833–843. [Google Scholar] [CrossRef] [PubMed]
  20. Zhao, R.; Zhou, M.; Chen, Y.; Cao, Y.; Zhang, R.; Li, Q. CRISPR/Cas9-Mediated BRCA1 Knockdown Adipose Stem Cells Promote Breast Cancer Progression. Plast. Reconstr. Surg. 2019, 143, 747–756. [Google Scholar] [CrossRef] [PubMed]
  21. Cells, S.N.; Wan, Z.; Mah, D.; Simtchouk, S.; Kluftinger, A. Human Adipose Tissue Conditioned Media from Lean Subjects Is Protective against H2O2 Induced Neurotoxicity in Human SH-SY5Y Neuronal Cells. Int. J. Mol. Sci. 2015, 16, 1221–1231. [Google Scholar] [CrossRef]
  22. Hillers, L.E.; D’Amato, J.V.; Chamberlin, T.; Paderta, G.; Arendt, L.M. Obesity-Activated Adipose-Derived Stromal Cells Promote Breast Cancer Growth and Invasion. Neoplasia 2018, 20, 1161–1174. [Google Scholar] [CrossRef]
  23. De Berti, M.; Goupille, C.; Doucet, M.; Arbion, F.; Vilde, A.; Body, G.; Ouldamer, L. Oncological Safety of Autologous Fat Grafting in Breast Reconstruction after Mastectomy for Cancer: A Case-Control Study. J. Gynecol. Obstet. Hum. Reprod. 2022, 51, 102257. [Google Scholar] [CrossRef]
  24. Navarro, A.-S.; Omalek, D.; Chaltiel, L.; Vaysse, C.; Meresse, T.; Gangloff, D.; Jouve, E.; Selmes, G. Oncologic safety of autologous fat grafting in primary breast reconstruction after mastectomy for cancer. Eur. J. Surg. Oncol. 2024, 50, 107998. [Google Scholar] [CrossRef] [PubMed]
  25. Descarrega, J.; Grande, L. Breast Cancer Recurrence Is Not Increased with Lipofilling Reconstruction. Ann. Plast. Surg. 2017, 79, 243–248. [Google Scholar] [CrossRef]
  26. Bunnell, B.A.; Martin, E.C.; Matossian, M.D.; Brock, C.K.; Nguyen, K.; Collins-Burow, B.; Burow, M.E. The effect of obesity on adipose-derived stromal cells and adipose tissue and their impact on cancer. Cancer Metastasis Rev. 2022, 41, 549–573. [Google Scholar] [CrossRef] [PubMed]
  27. Lucocq, J.; Baig, H.; Dixon, J.M. European Journal of Surgical Oncology The impact of immediate lipofilling on oncological outcomes, complication rates and patient reported outcomes in breast conserving surgery: A systematic review and meta-analysis. Eur. J. Surg. Oncol. 2025, 51, 110446. [Google Scholar] [CrossRef]
  28. Torto, F.L.; Patan, L.; Abbaticchio, D.; Pagnotta, A. Autologous Fat Grafting (AFG): A Systematic Review to Evaluate Oncological Safety in Breast Cancer Patients. J. Clin. Med. 2024, 13, 4369. [Google Scholar] [CrossRef] [PubMed]
  29. Takatani-Nakase, T.; Matsui, C.; Maeda, S.; Kawahara, S.; Takahashi, K. High glucose level promotes migration behavior of breast cancer cells through zinc and its transporters. PLoS ONE 2014, 9, e90136. [Google Scholar] [CrossRef]
  30. Biondo, L.A.; Batatinha, H.A.; Souza, C.O.; Teixeira, A.A.S.; Silveira, L.S.; Alonso-Vale, M.I.; Oyama, L.M.; Alves, M.J.; Seelaender, M.; Neto, J.C.R. Metformin mitigates fibrosis and glucose intolerance induced by doxorubicin in subcutaneous adipose tissue. Front. Pharmacol. 2018, 9, 452. [Google Scholar] [CrossRef]
  31. Takkar, S.; Kosmacek, E.A.; McDowell, J.A.; Liermann-Wooldrik, K.T.; Chatterjee, A.; Oberley-Deegan, R.E. Irradiated obese adipocytes are prone to oxidative stress, inflammation, senescence, and fibrosis. Sci. Rep. 2025, 15, 39844. [Google Scholar] [CrossRef]
  32. Piatkowski, A.A.; Wederfoort, J.L.M.; Hommes, J.E.; Schop, S.S.J.; Krastev, T.K.; van der Hulst, R.R.W.J. Effect of Total Breast Reconstruction with Autologous Fat Transfer Using an Expansion Device vs Implants on Quality of Life Among Patients with Breast Cancer: A Randomized Clinical Trial. JAMA Surg. 2023, 158, 456–464. [Google Scholar] [CrossRef]
  33. Wu, Q.; Li, B.; Li, Z.; Li, J.; Sun, S.; Sun, S. Cancer-associated adipocytes: Key players in breast cancer progression. J. Hematol. Oncol. 2019, 12, 95. [Google Scholar] [CrossRef]
  34. Padilla-Rodriguez, M.; Parker, S.S.; Adams, D.G.; Westerling, T.; Puleo, J.I.; Watson, A.W.; Hill, S.M.; Noon, M.; Gaudin, R.; Aaron, J.; et al. The actin cytoskeletal architecture of estrogen receptor positive breast cancer cells suppresses invasion. Nat. Commun. 2018, 9, 2980. [Google Scholar] [CrossRef]
  35. Sparano, J.A.; Zhao, F.; Martino, S.; Ligibel, J.A.; Perez, E.A.; Saphner, T.; Wolff, A.C.; Sledge, G.W., Jr.; Wood, W.C.; Davidson, N.E. Long-term follow-up of the E1199 phase III trial evaluating the role of taxane and schedule in operable breast cancer. J. Clin. Oncol. 2015, 33, 2353–2360. [Google Scholar] [CrossRef]
  36. Balaban, S.; Shearer, R.F.; Lee, L.S.; van Geldermalsen, M.; Schreuder, M.; Shtein, H.C.; Cairns, R.; Thomas, K.C.; Fazakerley, D.J.; Grewal, T.; et al. Adipocyte lipolysis links obesity to breast cancer growth: Adipocyte-derived fatty acids drive breast cancer cell proliferation and migration. Cancer Metab. 2017, 5, 1. [Google Scholar] [CrossRef] [PubMed]
  37. Bhardwaj, P.; Brown, K.A. Obese Adipose Tissue as a Driver of Breast Cancer Growth and Development: Update and Emerging Evidence. Front. Oncol. 2021, 11, 638918. [Google Scholar] [CrossRef] [PubMed]
  38. Lore, L.; Shearer, R.F.; Lee, L.S.; van Geldermalsen, M.; Schreuder, M.; Shtein, H.C.; Holst, J.; Hoy, A.J. Secretome analysis of breast cancer-associated adipose tissue to identify paracrine regulators of breast cancer growth. Oncotarget 2017, 8, 47239–47249. [Google Scholar] [CrossRef] [PubMed][Green Version]
  39. Zhang, K.; Chen, L.; Zheng, H.; Zeng, Y. Cytokines secreted from adipose tissues mediate tumor proliferation and metastasis in triple negative breast cancer. BMC Cancer 2022, 22, 886. [Google Scholar] [CrossRef]
  40. Kolb, R.; Sutterwala, F.S.; Zhang, W. Obesity and cancer: Inflammation bridges the two. Curr. Opin. Pharmacol. 2016, 29, 77–89. [Google Scholar] [CrossRef]
  41. Cui, Y.; Cui, S.; Lu, W.; Wang, Y.; Zhuo, Z.; Wang, R.; Zhang, D.; Wu, X.; Chang, L.; Zuo, X.; et al. CRP, IL-1α, IL-1β, and IL-6 levels and the risk of breast cancer: A two-sample Mendelian randomization study. Sci. Rep. 2024, 14, 1982. [Google Scholar] [CrossRef]
  42. Rosendahl, A.H.; Bergqvist, M.; Lettiero, B.; Kimbung, S.; Borgquist, S. Adipocytes and Obesity-Related Conditions Jointly Promote Breast Cancer Cell Growth and Motility: Associations with CAP1 for Prognosis. Front. Endocrinol. 2018, 9, 689. [Google Scholar] [CrossRef]
  43. Zhou, X.; Zhang, J.; Lv, W.; Zhao, C.; Xia, Y.; Wu, Y.; Zhang, Q. The pleiotropic roles of adipocyte secretome in remodeling breast cancer. J. Exp. Clin. Cancer Res. 2022, 41, 203. [Google Scholar] [CrossRef] [PubMed]
  44. Goossens, G.H. The Metabolic Phenotype in Obesity: Fat Mass, Body Fat Distribution, and Adipose Tissue Function. Obes. Facts 2017, 10, 207–215. [Google Scholar] [CrossRef] [PubMed]
  45. Longo, M.; Zatterale, F.; Naderi, J.; Parrillo, L.; Formisano, P.; Raciti, G.A.; Beguinot, F.; Miele, C. Adipose tissue dysfunction as determinant of obesity-associated metabolic complications. Int. J. Mol. Sci. 2019, 20, 2358. [Google Scholar] [CrossRef] [PubMed]
  46. Rowan, B.G.; Gimble, J.M.; Sheng, M.; Anbalagan, M.; Jones, R.K.; Frazier, T.P.; Asher, M.; Lacayo, E.A.; Friedlander, P.L.; Kutner, R.; et al. Human adipose tissue-derived stromal/stem cells promote migration and early metastasis of triple negative breast cancer xenografts. PLoS ONE 2014, 9, e89595. [Google Scholar] [CrossRef]
  47. Bischoff, M.C.; Lieb, S.; Renkawitz-Pohl, R.; Bogdan, S. Filopodia-based contact stimulation of cell migration drives tissue morphogenesis. Nat. Commun. 2021, 12, 791. [Google Scholar] [CrossRef]
  48. Nilufar, S.; Morrow, A.A.; Lee, J.M.; Perkins, T.J. FiloDetect: Automatic detection of filopodia from fluorescence microscopy images. BMC Syst. Biol. 2013, 7, 66. [Google Scholar] [CrossRef]
Cancers 18 00868 g001
Figure 1. An overview of the different study groups. ATCM (adipose tissue conditioned medium), NW = normal weight (BMI < 25), OW = overweight (25 ≤ BMI < 30). OB = obese (BMI ≥ 30).
Figure 1. An overview of the different study groups. ATCM (adipose tissue conditioned medium), NW = normal weight (BMI < 25), OW = overweight (25 ≤ BMI < 30). OB = obese (BMI ≥ 30).
Cancers 18 00868 g001
Cancers 18 00868 g002
Figure 2. Representative fluorescent images of cells showing filopodia activation in a scratch assay after 24 h. (A), overlay image of the scratch with cells stained with DAPI nuclei staining and F-actin staining (magnification 100×); (B), example of HPF (high power field) showing filopodia (magnification 400×); (C,D), Greyscale and Fire lookup table view image to identify activated filopodia (magnification 400×). The arrows indicate activated filopodia.
Figure 2. Representative fluorescent images of cells showing filopodia activation in a scratch assay after 24 h. (A), overlay image of the scratch with cells stained with DAPI nuclei staining and F-actin staining (magnification 100×); (B), example of HPF (high power field) showing filopodia (magnification 400×); (C,D), Greyscale and Fire lookup table view image to identify activated filopodia (magnification 400×). The arrows indicate activated filopodia.
Cancers 18 00868 g002
Cancers 18 00868 g003
Figure 3. Group 1. (A) Migration of MCF-7, MDA-MB-231 and SK-BR-3 cells with naïve adipose tissue derived ATCM as attractant. Delta cell index is corrected for positive and negative control. (B) percentage activated filopodia by naïve adipose tissue derived ATCM. Naïve adipose tissue induced migration in MCF-7 and MDA-MB-231 cells (A), with stronger filopodia activation in MDA-MB-231 (B). (* p < 0.005, ** p = 0.001, *** p < 0.001).
Figure 3. Group 1. (A) Migration of MCF-7, MDA-MB-231 and SK-BR-3 cells with naïve adipose tissue derived ATCM as attractant. Delta cell index is corrected for positive and negative control. (B) percentage activated filopodia by naïve adipose tissue derived ATCM. Naïve adipose tissue induced migration in MCF-7 and MDA-MB-231 cells (A), with stronger filopodia activation in MDA-MB-231 (B). (* p < 0.005, ** p = 0.001, *** p < 0.001).
Cancers 18 00868 g003
Cancers 18 00868 g004
Figure 4. Group 2. Activation of filopodia of MCF-7, MDA-MB-231 and SK-BR-3 cells by BRCA carriers-derived ATCM. BRCA adipose tissue induces filopodia activation. (*** p < 0.001) Positive and negative controls are not shown here because these are cell line-dependent and therefore cannot be integrated into this figure.
Figure 4. Group 2. Activation of filopodia of MCF-7, MDA-MB-231 and SK-BR-3 cells by BRCA carriers-derived ATCM. BRCA adipose tissue induces filopodia activation. (*** p < 0.001) Positive and negative controls are not shown here because these are cell line-dependent and therefore cannot be integrated into this figure.
Cancers 18 00868 g004
Cancers 18 00868 g005
Figure 5. Group 3. Migration and activation induced by BC ATCM. Dotted black line represents zero migration, green line positive control (20% FCS) and red line represents negative control (5% FCS.) for the filopodia activation. ER+ ATCM suppresses migration in MCF-7 cells, it strongly enhances filopodia activation (A,B). TNBC ATCM both stimulates migration and filopodia activation in MDA-MB-231 cells, producing the strongest pro-invasive response among all groups and subtypes (C,D). HER2+ ATCM enhances filopodia activation but does not induce migration in SK-BR-3 cells (E,F). (* p < 0.005, *** p < 0.001).
Figure 5. Group 3. Migration and activation induced by BC ATCM. Dotted black line represents zero migration, green line positive control (20% FCS) and red line represents negative control (5% FCS.) for the filopodia activation. ER+ ATCM suppresses migration in MCF-7 cells, it strongly enhances filopodia activation (A,B). TNBC ATCM both stimulates migration and filopodia activation in MDA-MB-231 cells, producing the strongest pro-invasive response among all groups and subtypes (C,D). HER2+ ATCM enhances filopodia activation but does not induce migration in SK-BR-3 cells (E,F). (* p < 0.005, *** p < 0.001).
Cancers 18 00868 g005
Table 1. Patient characteristics.
Table 1. Patient characteristics.
NaïveBRCA MutationER+ BCTNBC BCHER2+ BC
BMI * mean ± SD (n)26.7 ± 4.3 (n = 20)27.0 ± 3.8 (n = 22)32.4 ± 3.3 (n = 19)27.7 ± 6.3 (n = 12)26.8 ± 5.1 (n = 7)
Normal weight 122.9 ± 2.0 (n = 9)22.6 ± 1.8 (n = 7)23.4 ± 1.2 (n = 6)21.8 ± 1.8 (n = 4)21.5 ± 1.6 (n = 3)
Overweight 227.2 ± 1.1 (n = 5)27.5 ± 1.5 (n = 8)27.3 ± 1.6 (n = 9)28.0 ± 0.8 (n = 5)29.7 (n = 1)
Obese 331.9 ± 2.3 (n = 6)31.0 ± 1.9 (n = 7)37.0 ± 1.1 (n = 4)35.0 ± 7.7 (n = 3)31.1 ± 1.0 (n = 3)
age34 ± 1433 ± 957.3 ± 1449 ± 1558 ± 15
Neo-adjuvant
treatment (%)		0%0%0%30.7%14.3%
* Body mass index, 1. BMI ≤ 25 normal weight, 2. 25 < BMI > 30 overweight and 3. BMI ≥ 30 obese.
Table 2. Luminex assay naïve versus BC adipose tissue.
Table 2. Luminex assay naïve versus BC adipose tissue.
Marker/CytokineHighest SampleTest StatisticsSESDp (Corrected)
CD40BC1051.5103.82.40.015
FGF bBC1019.0103.82.10.033
FIT3_LBC1053.0103.82.50.014
GM_CSFBC1111.5103.83.00.003
GranymeBBC1010.5103.82.00.041
GRO_BBC1028.0103.82.20.027
IFN_alfaBC1012.5103.82.10.039
IL12p70BC1031.5103.52.30.024
IL15BC1019.5103.72.10.033
IL17BC1070.0102.92.60.008
IL1BBC1068.0103.32.60.009
IL1RABC1022.0103.82.20.031
IL2BC1129.5103.83.20.001
IL3BC1093.5103.72.90.004
IL5BC1012.099.42.20.031
IL6BC1052.5103.82.50.014
IL7BC1031.5103.72.30.024
IL8BC1122.0103.83.10.002
Lymfotoxin_aBC1079.0103.62.70.007
PDGF_AABC1161.0103.83.5<0.001
TGF aBC1069.5103.62.60.009
VEGFBC1143.5103.83.3<0.001
adiponectinNon BC400.0101.3−3.9<0.001
LeptinNon BC200.0103.8−5.8<0.001
Serpin E1Non BC584.0584.0−2.10.037
TNF-AlfaNon BC1331.0590.0−2.00.045
Table 3. Luminex assay shows differences in cytokine presence in adipose tissue between different BMI groups.
Table 3. Luminex assay shows differences in cytokine presence in adipose tissue between different BMI groups.
Marker/CytokineSamples *Test StatisticsSESDp (Corrected)
IL1RANW-OW−16.86.1−2.80.018
NW-OB−20.46.5−3.10.005
CRPNW-OB−18.06.5−2.80.017
OW-OB−17.26.6−2.60.029
* Bold sample contained the highest cytokine presence.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Holt-Kedde, I.L.; Timmer-Bosscha, H.; Kruyt, F.A.E.; Kelder, W.; van der Vegt, B.; Zwager, M.C.; Schröder, C.P.; Arjaans, M. Effect of Healthy and Tumor-Associated Breast Adipose Tissue on Breast Cancer Cell Migration and Activation. Cancers 2026, 18, 868. https://doi.org/10.3390/cancers18050868

AMA Style

Holt-Kedde IL, Timmer-Bosscha H, Kruyt FAE, Kelder W, van der Vegt B, Zwager MC, Schröder CP, Arjaans M. Effect of Healthy and Tumor-Associated Breast Adipose Tissue on Breast Cancer Cell Migration and Activation. Cancers. 2026; 18(5):868. https://doi.org/10.3390/cancers18050868

Chicago/Turabian Style

Holt-Kedde, Iris L., Hetty Timmer-Bosscha, Frank A. E. Kruyt, Wendy Kelder, Bert van der Vegt, Mieke C. Zwager, Carolien P. Schröder, and Marlous Arjaans. 2026. "Effect of Healthy and Tumor-Associated Breast Adipose Tissue on Breast Cancer Cell Migration and Activation" Cancers 18, no. 5: 868. https://doi.org/10.3390/cancers18050868

APA Style

Holt-Kedde, I. L., Timmer-Bosscha, H., Kruyt, F. A. E., Kelder, W., van der Vegt, B., Zwager, M. C., Schröder, C. P., & Arjaans, M. (2026). Effect of Healthy and Tumor-Associated Breast Adipose Tissue on Breast Cancer Cell Migration and Activation. Cancers, 18(5), 868. https://doi.org/10.3390/cancers18050868

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop